Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03109470Withdrawn

The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

Role: lead

NCT01489384Unknown

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Role: lead

NCT01692912Not ApplicableWithdrawn

Psoriatic Arthritis Treat to Target vs. Usual Care

Role: lead

NCT01749618Not ApplicableCompleted

Closing the Gap in Care in Seronegative Inflammatory Arthritis

Role: lead

All 4 trials loaded